Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have earned an average recommendation of "Buy" from the nine ratings firms that are presently covering the firm, MarketBeat.com reports. Eight research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $22.29.

Several brokerages have commented on ZVRA. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group upped their price target on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the stock a "buy" rating in a report on Thursday, March 13th. JMP Securities set a $18.00 price objective on shares of Zevra Therapeutics in a report on Wednesday, March 12th. Guggenheim upped their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the stock a "buy" rating in a research note on Thursday, March 13th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $20.00 price target on shares of Zevra Therapeutics in a research note on Thursday, March 13th.

Insider Activity at Zevra Therapeutics

In other news, EVP Joshua Schafer sold 10,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the sale, the executive vice president now owns 29,486 shares in the company, valued at approximately $231,759.96. This represents a 26.26 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director John B. Bode bought 10,000 shares of the company's stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average price of $7.96 per share, for a total transaction of $79,600.00. Following the completion of the purchase, the director now owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 85,773 shares of company stock valued at $674,176 over the last quarter. 2.40% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Zevra Therapeutics

A number of large investors have recently modified their holdings of ZVRA. Readystate Asset Management LP increased its stake in Zevra Therapeutics by 924.6% during the 1st quarter. Readystate Asset Management LP now owns 683,032 shares of the company's stock valued at $5,116,000 after purchasing an additional 616,370 shares in the last quarter. AIGH Capital Management LLC lifted its position in Zevra Therapeutics by 82.4% during the 1st quarter. AIGH Capital Management LLC now owns 1,438,109 shares of the company's stock worth $10,771,000 after acquiring an additional 649,495 shares during the period. Mystic Asset Management Inc. grew its stake in Zevra Therapeutics by 8.2% during the 1st quarter. Mystic Asset Management Inc. now owns 338,902 shares of the company's stock valued at $2,538,000 after purchasing an additional 25,555 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Zevra Therapeutics by 11.0% during the first quarter. Bank of New York Mellon Corp now owns 120,433 shares of the company's stock worth $902,000 after purchasing an additional 11,946 shares during the period. Finally, Carret Asset Management LLC acquired a new position in Zevra Therapeutics in the 1st quarter worth approximately $271,000. Hedge funds and other institutional investors own 35.03% of the company's stock.

Zevra Therapeutics Trading Down 7.5 %

NASDAQ ZVRA traded down $0.60 on Thursday, hitting $7.40. 424,427 shares of the stock were exchanged, compared to its average volume of 617,732. Zevra Therapeutics has a 52-week low of $4.20 and a 52-week high of $9.76. The firm has a market capitalization of $404.62 million, a P/E ratio of -3.76 and a beta of 1.87. The company has a debt-to-equity ratio of 0.84, a quick ratio of 2.88 and a current ratio of 2.88. The stock has a fifty day moving average price of $7.51 and a two-hundred day moving average price of $8.08.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last issued its quarterly earnings results on Tuesday, March 11th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.28). The firm had revenue of $12.00 million for the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. Research analysts forecast that Zevra Therapeutics will post -1.95 EPS for the current fiscal year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.